Technical Analysis for EMMA - Emmaus Life Sciences Inc

Grade Last Price % Change Price Change
grade D 1.85 -2.63% -0.0500
EMMA closed down 2.63 percent on Monday, December 9, 2019, on 55 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
See historical EMMA trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -2.63%
Down 3 Days in a Row Weakness -2.63%
Down 4 Days in a Row Weakness -2.63%
Down 5 Days in a Row Weakness -2.63%
Lower Bollinger Band Touch Weakness -2.63%
Older signals for EMMA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Medicine Health Medical Specialties Pharmaceutical Medication Therapeutic Products Sickle Cell Disease Rare And Orphan Diseases Therapeutic Cell Sheet Technology Corneal Diseases Diverticulosis Endari Glutamine Treatment Of Corneal Diseases

Is EMMA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.85
52 Week Low 1.33
Average Volume 17,560
200-Day Moving Average 0.0000
50-Day Moving Average 2.4984
20-Day Moving Average 2.4143
10-Day Moving Average 2.1845
Average True Range 0.2117
ADX 31.48
+DI 11.8732
-DI 35.3156
Chandelier Exit (Long, 3 ATRs ) 2.3649
Chandelier Exit (Short, 3 ATRs ) 2.4351
Upper Bollinger Band 3.0313
Lower Bollinger Band 1.7973
Percent B (%b) 0.04
BandWidth 51.1121
MACD Line -0.1894
MACD Signal Line -0.1187
MACD Histogram -0.0707
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.0750
Resistance 3 (R3) 2.0967 2.0433 2.0375
Resistance 2 (R2) 2.0433 1.9860 2.0325 2.0250
Resistance 1 (R1) 1.9467 1.9506 1.9950 1.9250 2.0125
Pivot Point 1.8933 1.8933 1.9175 1.8825 1.8933
Support 1 (S1) 1.7967 1.8360 1.8450 1.7750 1.6875
Support 2 (S2) 1.7433 1.8006 1.7325 1.6750
Support 3 (S3) 1.6467 1.7433 1.6625
Support 4 (S4) 1.6250